GO:0035877 death effector domain binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0035877 (death effector domain binding) is a molecular function defined as binding to a DED domain, a six-helix homotypic protein interaction module structurally related to the death domain.
• DED binding underlies assembly of death-inducing signaling complexes that control apoptosis, necroptosis, and inflammation.
• The DED protein family includes FADD, procaspase-8/10, cFLIP, PEA-15, and DEDD, which act as adaptors, regulators, or scaffolds.
• DED-mediated interactions, such as RIPK1-FADD binding, are essential for perinatal survival and immune homeostasis in mice.
• DED-containing proteins are linked to cancer, including triple-negative breast cancer vulnerability to cell cycle inhibition.
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable precise interrogation of DED binding interfaces and their disease relevance.
Description
GO:0035877, death effector domain binding, is a molecular function describing the selective interaction of a protein with a death effector domain (DED). The DED is a homotypic protein interaction module composed of a bundle of six alpha-helices that is structurally related to the death domain (DD). This binding activity is central to the assembly of oligomeric signaling platforms that transmit extracellular death signals into intracellular caspase activation and inflammatory responses. Researchers study DED binding because it governs the specificity and stoichiometry of death receptor signaling complexes, and because its dysregulation is implicated in autoimmunity, cancer, and inflammatory disease. The DED protein family includes adaptor and regulatory proteins such as FADD, procaspase-8, procaspase-10, cFLIP, PEA-15, and DEDD, all of which engage in DED-DED interactions. Understanding GO:0035877 therefore provides a mechanistic entry point for dissecting apoptosis, necroptosis, and immune signaling at the molecular level. Because DED binding is a homotypic interaction, it is amenable to targeted perturbation by CRISPR-based genome editing, making it a tractable function for functional genomics.
death effector domain binding At A Glance
| GO ID | GO:0035877 |
|---|---|
| GO term | death effector domain binding |
| Ontology | molecular_function |
| Synonym | DED binding |
| Definition | Binding to a DED domain of a protein, a homotypic protein interaction module composed of a bundle of six alpha-helices that is related in structure to the death domain (DD). |
| Major function | Mediates homotypic DED-DED interactions that assemble death-inducing signaling complexes and regulate caspase activation. |
| Representative proteins | FADD, procaspase-8, procaspase-10, cFLIP, PEA-15, DEDD. |
| Related structural module | Death domain (DD), sharing a six-helix bundle fold. |
| Disease relevance | Cancer, autoimmunity, and inflammatory signaling. |
What Is GO:0035877?
In our own words, GO:0035877 describes the function of a protein that physically binds to a death effector domain (DED) of another protein. The DED is a compact, six-alpha-helical bundle that mediates homotypic protein-protein interactions and is structurally related to the death domain. This binding function is what allows DED-containing proteins to nucleate and organize signaling complexes rather than merely serving as passive scaffolds.
Why Is death effector domain binding Important in Cell Biology?
DED binding is important because it is the molecular event that converts receptor-proximal death signals into caspase activation and inflammatory output. Without correctly regulated DED-DED interactions, cells cannot properly execute apoptosis or necroptosis, and immune homeostasis is disrupted. The interaction between RIPK1 and FADD, which depends on death domain and DED-containing adaptors, controls perinatal lethality and inflammation in mice, underscoring the physiological importance of these binding events. In cancer, DED-containing proteins such as DEDD can induce vulnerability to cell cycle inhibition in triple-negative breast cancer, linking DED biology to therapeutic strategy. Thus, GO:0035877 is a functionally and clinically significant molecular activity.
• Controls assembly of death-inducing signaling complexes that initiate apoptosis.
• Regulates caspase-8 and caspase-10 activation downstream of death receptors.
• Modulates necroptosis and inflammatory signaling through RIPK1-FADD interactions.
• Maintains immune homeostasis and perinatal survival in mouse models.
• Is dysregulated in cancer, including triple-negative breast cancer.
• Provides a druggable and editable interface for therapeutic intervention.
• Serves as a paradigm for homotypic interaction modules related to the death domain.
• Enables functional genomics studies using CRISPR knockout and knock-in models.
Molecular Mechanism of death effector domain binding
DED fold and homotypic recognition
In simple terms: DED domains stick to each other because they share a compatible six-helix shape.
The death effector domain is a bundle of six alpha-helices structurally related to the death domain, and this fold supports homotypic DED-DED contacts. These contacts are the physical basis of GO:0035877, allowing proteins such as FADD and procaspase-8 to recognize one another. The DED protein family is defined by this shared interaction module, which confers specificity in signaling complex assembly.
Nucleation of death-inducing signaling complexes
In simple terms: DED binding acts like molecular Velcro that builds a platform for cell death signaling.
DED-mediated binding nucleates oligomeric platforms that recruit and activate initiator caspases. FADD uses its DED to engage procaspase-8 and procaspase-10, promoting proximity-induced activation. Regulatory proteins such as cFLIP and PEA-15 also contain DEDs and modulate these assemblies, fine-tuning the threshold for apoptosis.
Caspase activation and substrate processing
In simple terms: Once the DED platform forms, caspases switch on and cleave downstream targets.
Binding of DED-containing adaptors to initiator caspases drives conformational changes that enable caspase activation. Activated caspase-8 then cleaves effector caspases and other substrates to execute apoptosis. This step links GO:0035877 directly to the biochemical output of death receptor signaling.
Crosstalk with necroptosis and inflammation
In simple terms: DED binding also influences inflammatory cell death pathways.
The interaction between RIPK1 and FADD, which involves death domain and DED-containing components, controls perinatal lethality and inflammation. This crosstalk means that DED binding is not confined to apoptosis but also shapes necroptotic and inflammatory outcomes. Such dual roles make GO:0035877 relevant to both cell death and immune regulation.
Regulation by stoichiometry and post-translational control
In simple terms: How much of each DED protein is present, and how it is modified, decides whether signaling proceeds.
The balance between procaspase-8, cFLIP, and other DED proteins determines whether DED binding leads to caspase activation or inhibition. Post-translational modifications and protein abundance therefore act as rheostats on GO:0035877. In cancer, altered expression of DED-containing proteins such as DEDD can shift these balances and create therapeutic vulnerabilities.
Key Genes Involved in GO:0035877 death effector domain binding
The following genes encode DED-containing or DED-binding proteins that are central to GO:0035877 and its downstream biology.
| Gene | Major Role | Research Relevance |
|---|---|---|
| FADD | Adaptor that binds DED-containing caspases and RIPK1 | Core node for apoptosis and inflammation studies |
| CASP8 | Initiator caspase with DEDs that binds FADD | Key effector of death receptor-induced apoptosis |
| CASP10 | Initiator caspase with DEDs | Modulates death receptor signaling |
| CFLIP | DED-containing regulator of caspase-8 | Controls apoptosis threshold and NF-kB signaling |
| PEA15 | DED-containing scaffold | Regulates integrin and death signaling |
| DEDD | DED-containing protein | Linked to triple-negative breast cancer vulnerability |
| RIPK1 | Kinase interacting with FADD | Controls perinatal lethality and inflammation |
| TNFRSF1A | Death receptor upstream of DED complexes | Context for DED binding studies |
| FAS | Death receptor that recruits FADD | Model for DED-dependent apoptosis |
| TNFRSF10A | TRAIL receptor recruiting FADD | Model for DED-dependent apoptosis |
| TNFRSF10B | TRAIL receptor recruiting FADD | Model for DED-dependent apoptosis |
| CASP3 | Effector caspase downstream of DED signaling | Readout of DED-dependent apoptosis |
| CASP7 | Effector caspase downstream of DED signaling | Readout of DED-dependent apoptosis |
| BID | BH3-only protein linking DED signaling to mitochondria | Amplifies apoptosis |
| NINJ1 | Membrane rupture effector with structural parallels to DED-like folds | Context for regulated lysis |
| TIR | Plant immune TIR domain proteins forming condensates | Comparative scaffold biology |
| EDS1 | Plant immunity component | Comparative autoimmunity context |
How Is death effector domain binding Regulated?
DED binding is regulated by the relative abundance and post-translational status of DED-containing proteins, which set the threshold for caspase activation. The balance between procaspase-8 and cFLIP is a key determinant of whether DED complexes promote or inhibit apoptosis. In vivo, the RIPK1-FADD interaction is required to restrain perinatal lethality and inflammation, indicating that DED-dependent complexes are under tight physiological control. In cancer, altered expression of DED proteins such as DEDD can rewire cell cycle checkpoints and create sensitivity to inhibition. Comparative studies in plants show that TIR domain proteins can be activated by substrate-induced condensation, illustrating that oligomerization-based regulation is a broader theme in immune signaling.
death effector domain binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| DEDD | Triple-negative breast cancer | Knockout and overexpression in breast cancer cell lines |
| RIPK1 | Perinatal lethality and inflammation | Knock-in and point-mutation mouse models |
| FADD | Apoptosis and inflammation | Knockout cell lines and mouse models |
| CASP8 | Death receptor signaling disorders | Knockout and point-mutation models |
| CFLIP | Apoptosis threshold and NF-kB signaling | Overexpression and knockout models |
Cancer
DED-containing proteins contribute to cancer biology; DEDD induces vulnerability to cell cycle inhibition in triple-negative breast cancer, suggesting that DED-dependent signaling can be exploited therapeutically. Dysregulated apoptosis and necroptosis pathways involving DED binding are common features of tumorigenesis.
Inflammatory and autoimmune conditions
The RIPK1-FADD interaction controls perinatal lethality and inflammation, linking DED-dependent complexes to inflammatory disease mechanisms. Autoimmunity in plants also involves death-fold signaling components, highlighting the evolutionary conservation of these regulatory modules.
Cell death disorders
Because DED binding is required for death receptor-induced apoptosis, defects in these interactions can cause inappropriate cell survival or excessive cell death. Such imbalances are relevant to degenerative and immune disorders.
From death effector domain binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of DED binding abolish apoptosis? | CRISPR knockout of FADD or CASP8 |
| Which residues mediate DED-DED contact? | Point-mutation knock-in of DED interface residues |
| Can a tagged DED protein be tracked in live cells? | Knock-in of fluorescent or epitope tags |
| Does overexpression of a DED protein shift apoptosis threshold? | Doxycycline-inducible overexpression |
| Does DEDD loss alter cell cycle sensitivity? | Knockout in triple-negative breast cancer cells |
| Does RIPK1-FADD binding prevent inflammation? | Knock-in and knockout mouse models |
How to Study the death effector domain binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Co-immunoprecipitation | Physical DED-DED interactions | Confirm binding in cells |
| GST pull-down | Direct protein-protein binding | Map DED interfaces |
| Crystallography / cryo-EM | Three-dimensional DED structure | Define binding surface |
| Caspase activity assay | Downstream caspase activation | Functional readout of DED signaling |
| Annexin V flow cytometry | Apoptotic cell death | Phenotype of DED perturbations |
| CRISPR knockout screening | Gene requirement for fitness | Identify DED pathway dependencies |
| Knock-in tagging | Protein localization and dynamics | Track DED proteins in live cells |
| Transcriptomics | Expression changes after perturbation | Contextualize DED signaling |
Co-immunoprecipitation and pull-down assays
Co-immunoprecipitation and GST pull-down assays are standard methods to detect DED-DED interactions and confirm GO:0035877 in cell lysates. These approaches can map which DED-containing proteins associate under specific signaling conditions.
Structural biology and modeling
Because the DED is a six-helix bundle related to the death domain, structural methods such as crystallography and cryo-EM can define the binding interface. Structural data guide mutagenesis of DED contact residues for functional testing.
Cell death and caspase activity assays
Apoptosis and caspase activity assays measure the functional consequence of DED binding, linking molecular interactions to cell fate. These readouts are used to test whether DED-binding perturbations alter death receptor signaling.
CRISPR-based functional genomics
CRISPR knockout and knock-in screens can systematically test the requirement for DED-binding proteins in apoptosis, inflammation, and cancer cell fitness. Such screens connect GO:0035877 to disease-relevant phenotypes.
How CRISPR Can Be Used to Study GO:0035877 death effector domain binding
Knockout
CRISPR knockout of DED-containing genes such as FADD, CASP8, or DEDD can abolish DED binding and reveal its requirement for apoptosis, inflammation, and cancer cell fitness. Knockout models are foundational for assigning causality to GO:0035877 in specific phenotypes.
Point Mutation
Point-mutation knock-in of residues at the DED-DED interface allows precise testing of which contacts are required for binding and signaling. Such models distinguish binding-dependent from scaffolding functions.
Knock-in
Knock-in of epitope or fluorescent tags enables tracking of DED proteins and their complexes in live cells, linking GO:0035877 to spatiotemporal signaling dynamics. Knock-in of disease-associated variants can model altered DED binding in vivo.
Overexpression
Overexpression of DED-containing proteins such as cFLIP or DEDD can shift apoptosis thresholds and cell cycle sensitivity, providing gain-of-function evidence for DED binding in disease models. Inducible overexpression systems allow dose- and time-controlled experiments.
How EDITGENE Supports death effector domain binding Research
Researchers studying death effector domain binding-related genes often need to determine whether a candidate gene is causally involved in apoptosis, inflammation, or cancer phenotypes, and which protein interfaces mediate the effect. EDITGENE provides the CRISPR and bioinformatics toolkit to move from correlation to mechanism.
Contact EDITGENE today to design your custom CRISPR model for death effector domain binding research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| FADD Knockout HEK293 Cell Line | EDJ-KQ1473 | Human | 8772 | Details Get a Quote |
| CASP8 Knockout HEK293 Cell Line | EDJ-KQ1474 | Human | 841 | Details Get a Quote |
| CASP10 Knockout HEK293 Cell Line | EDJ-KQ1476 | Human | 843 | Details Get a Quote |
| FADD Knockout A-549 Cell Line | EDJ-KQ21049 | Human | 8772 | Details Get a Quote |
| FADD Knockout HCT 116 Cell Line | EDJ-KQ21050 | Human | 8772 | Details Get a Quote |
| FADD Knockout HeLa Cell Line | EDJ-KQ21051 | Human | 8772 | Details Get a Quote |
| CASP8 Knockout A-549 Cell Line | EDC07644 | Human | 841 | Details Get a Quote |
| CASP8 Knockout HCT 116 Cell Line | EDJ-KQ21053 | Human | 841 | Details Get a Quote |
| CASP10 Knockout A-549 Cell Line | EDJ-KQ21054 | Human | 843 | Details Get a Quote |
| CASP10 Knockout HCT 116 Cell Line | EDJ-KQ21055 | Human | 843 | Details Get a Quote |
| CASP10 Knockout HeLa Cell Line | EDJ-KQ21056 | Human | 843 | Details Get a Quote |
| CASP8 Knockout HeLa Cell Line | EDJ-KQ19719 | Human | 841 | Details Get a Quote |
| Fadd Knockout 32D Cell Line | EDJ-KZ231 | Mouse | 14082 | Details Get a Quote |
| NOL3 Knockout HEK293 Cell Line | EDJ-KQ50838 | Human | 8996 | Details Get a Quote |
| NOL3 Knockout HeLa Cell Line | EDJ-KQ55052 | Human | 8996 | Details Get a Quote |
Displaying Records 1 To 15 Of 19 Records
Frequently Asked Questions About death effector domain binding
What is death effector domain binding?
Death effector domain binding (GO:0035877) is the molecular function of binding to a DED domain, a six-helix homotypic interaction module related to the death domain.
What genes are involved in death effector domain binding?
Key genes include FADD, CASP8, CASP10, CFLIP, PEA15, and DEDD, all of which encode DED-containing proteins.
What is the GO ID for death effector domain binding?
The GO ID is GO:0035877, under the molecular_function ontology.
How does death effector domain binding regulate apoptosis?
DED binding nucleates death-inducing signaling complexes that recruit and activate initiator caspases such as caspase-8.
Is death effector domain binding involved in cancer?
Yes, DED-containing proteins such as DEDD are linked to triple-negative breast cancer vulnerability to cell cycle inhibition.
What is the role of FADD in death effector domain binding?
FADD is a DED-containing adaptor that binds procaspase-8 and RIPK1 to assemble death and inflammatory signaling complexes.
How can I study death effector domain binding with CRISPR?
CRISPR knockout, point-mutation knock-in, tagged knock-in, and overexpression models allow precise interrogation of DED interactions and their phenotypes.
What diseases are associated with death effector domain binding?
DED binding is associated with cancer, inflammatory conditions, and cell death disorders, including phenotypes controlled by RIPK1-FADD interactions.
What methods detect death effector domain binding?
Co-immunoprecipitation, GST pull-down, structural biology, caspase assays, and CRISPR screens are commonly used.
Why is death effector domain binding important for drug discovery?
Because DED interactions control apoptosis and inflammation, they represent editable and potentially druggable nodes for therapeutic intervention.
Conclusion
GO:0035877, death effector domain binding, is a central molecular function that assembles death-inducing signaling complexes and shapes apoptosis, necroptosis, and inflammation. Its dysregulation is linked to cancer and inflammatory disease, and the RIPK1-FADD interaction is required for perinatal survival and immune homeostasis. CRISPR-based knockout, point-mutation, knock-in, and overexpression models provide the precision needed to dissect DED binding interfaces and translate them into therapeutic insight.
References
- 1. Valmiki MG et al.. 2009. Death effector domain-containing proteins.. Cell Mol Life Sci 66(5):814-30 PMID: 18989622
- 2. Pourmal S et al.. 2025. Autoinhibition of dimeric NINJ1 prevents plasma membrane rupture.. Nature 637(8045):446-452 PMID: 39476863
- 3. Chakraborty J et al.. 2018. Autoimmunity in plants.. Planta 248(4):751-767 PMID: 30046903
- 4. Song W et al.. 2024. Substrate-induced condensation activates plant TIR domain proteins.. Nature 627(8005):847-853 PMID: 38480885
- 5. Tibbetts MD et al.. 2003. The death effector domain protein family: regulators of cellular homeostasis.. Nat Immunol 4(5):404-9 PMID: 12719729
- 6. Barnhart BC et al.. 2003. The death effector domain protein family.. Oncogene 22(53):8634-44 PMID: 14634625
- 7. Ni Y et al.. 2019. Death effector domain-containing protein induces vulnerability to cell cycle inhibition in triple-negative breast cancer.. Nat Commun 10(1):2860 PMID: 31253784
- 8. Rodriguez DA et al.. 2024. The interaction between RIPK1 and FADD controls perinatal lethality and inflammation.. Cell Rep 43(6):114335 PMID: 38850531
